FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007509924> ?p ?o ?g. }

• W2007509924 endingPage "63" @default.
• W2007509924 startingPage "59" @default.
• W2007509924 abstract "More than 50% of brain metastases (BMs) occur in advanced non-small cell lung cancer (NSCLC) patients. Untreated patients with BMs have a poor prognosis with a median survival of 2 months. In most cases BMs are multiple and their optimal therapy is whole-brain radiation therapy (WBRT). The role of systemic therapies for these patients is still a matter for investigation due to concerns about the ability of these drugs to cross the blood-brain barrier (BBB). Cisplatin (CDDP) remains the backbone for medical treatment of NSCLC and fotemustine (FTM) is a nitrosurea able to cross the BBB.Patients with advanced NSCLC, ECOG performance status (PS) 0-1 and multiple BMs not amenable to surgery or stereotactic radiotherapy were treated with 2 cycles of FTM 80 mg/m(2) days 1, 8 and CDDP 80 mg/m(2) day 1, every 3 weeks followed by WBRT 30 Gy (3 Gy daily in 10 fractions). Radiological restaging was performed before WBRT to assess the role of chemotherapy both for cranial and extracranial disease. Patients with disease control (DC: complete response plus partial response) received 4 more cycles. To assess the basic activities of daily living (ADL), the Barthel ADL Index was used to score patients' performance every 2 cycles. The trial design provides a two-step evaluation according to the optimal two-stage design of Simon. In the first phase 29 patients were enrolled in order to verify if this schedule showed more than 25% response rate both for cranial and extracranial disease. If so, enrollment added up to a total of 81 patients.After the first evaluation 4 out of 29 patients were excluded from the study (3 untreated/1 not included for administrative reasons). At the time of the planned interim analysis patient's characteristics were the following: median age 61 years (range 44-70), M/F = 16/9, adenocarcinoma 11, squamous 5, large cell 2, undefined NSCLC 7; PS 0/1 in 11/14 cases, median Barthel Index score was 20 [13-20]. Three (12%) partial responses were observed, 9 subjects (36%) with stable disease and 13 (52%) showing disease progression. These data did not satisfy the pre-planned hypothesis and the study was stopped. At the time of the first evaluation before WBRT 12/25 (48%) patients had a systemic DC in contrast with 15/25 (60%) patients with BMs DC. Chemotherapy was relatively well tolerated with a prevalence of asthenia as the most relevant specific toxicity while the haematological toxicity was mild.CDDP and FTM combined with WBRT do not represent a therapeutic option for patients with NSCLC. Therefore further studies to evaluate the combination of systemic treatments with WBRT are warranted." @default.
• W2007509924 created "2016-06-24" @default.
• W2007509924 creator A5004725964 @default.
• W2007509924 creator A5006970882 @default.
• W2007509924 creator A5013748999 @default.
• W2007509924 creator A5021158045 @default.
• W2007509924 creator A5038331440 @default.
• W2007509924 creator A5046785006 @default.
• W2007509924 creator A5048720703 @default.
• W2007509924 creator A5054443196 @default.
• W2007509924 creator A5062643447 @default.
• W2007509924 creator A5086984759 @default.
• W2007509924 date "2011-04-01" @default.
• W2007509924 modified "2023-10-16" @default.
• W2007509924 title "Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)" @default.
• W2007509924 cites W1971312769 @default.
• W2007509924 cites W1973799874 @default.
• W2007509924 cites W2004319861 @default.
• W2007509924 cites W2027372248 @default.
• W2007509924 cites W2029409133 @default.
• W2007509924 cites W2033434079 @default.
• W2007509924 cites W2037139573 @default.
• W2007509924 cites W2046858002 @default.
• W2007509924 cites W2047930883 @default.
• W2007509924 cites W2078763461 @default.
• W2007509924 cites W2095265260 @default.
• W2007509924 cites W2113465576 @default.
• W2007509924 cites W2114847324 @default.
• W2007509924 cites W2119366998 @default.
• W2007509924 cites W2132495825 @default.
• W2007509924 cites W2135121296 @default.
• W2007509924 cites W2137510882 @default.
• W2007509924 cites W2139248078 @default.
• W2007509924 cites W2139554501 @default.
• W2007509924 cites W2148934793 @default.
• W2007509924 cites W2153106027 @default.
• W2007509924 cites W2166399931 @default.
• W2007509924 cites W2168161641 @default.
• W2007509924 cites W2170198208 @default.
• W2007509924 cites W2533301708 @default.
• W2007509924 cites W2942864598 @default.
• W2007509924 doi "https://doi.org/10.1016/j.lungcan.2010.07.013" @default.
• W2007509924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20728237" @default.
• W2007509924 hasPublicationYear "2011" @default.
• W2007509924 type Work @default.
• W2007509924 sameAs 2007509924 @default.
• W2007509924 citedByCount "12" @default.
• W2007509924 countsByYear W20075099242012 @default.
• W2007509924 countsByYear W20075099242013 @default.
• W2007509924 countsByYear W20075099242014 @default.
• W2007509924 countsByYear W20075099242016 @default.
• W2007509924 countsByYear W20075099242019 @default.
• W2007509924 crossrefType "journal-article" @default.
• W2007509924 hasAuthorship W2007509924A5004725964 @default.
• W2007509924 hasAuthorship W2007509924A5006970882 @default.
• W2007509924 hasAuthorship W2007509924A5013748999 @default.
• W2007509924 hasAuthorship W2007509924A5021158045 @default.
• W2007509924 hasAuthorship W2007509924A5038331440 @default.
• W2007509924 hasAuthorship W2007509924A5046785006 @default.
• W2007509924 hasAuthorship W2007509924A5048720703 @default.
• W2007509924 hasAuthorship W2007509924A5054443196 @default.
• W2007509924 hasAuthorship W2007509924A5062643447 @default.
• W2007509924 hasAuthorship W2007509924A5086984759 @default.
• W2007509924 hasConcept C126322002 @default.
• W2007509924 hasConcept C143998085 @default.
• W2007509924 hasConcept C146357865 @default.
• W2007509924 hasConcept C151730666 @default.
• W2007509924 hasConcept C2776256026 @default.
• W2007509924 hasConcept C2776694085 @default.
• W2007509924 hasConcept C2777910003 @default.
• W2007509924 hasConcept C2778239845 @default.
• W2007509924 hasConcept C2778822529 @default.
• W2007509924 hasConcept C31760486 @default.
• W2007509924 hasConcept C509974204 @default.
• W2007509924 hasConcept C71924100 @default.
• W2007509924 hasConcept C86803240 @default.
• W2007509924 hasConceptScore W2007509924C126322002 @default.
• W2007509924 hasConceptScore W2007509924C143998085 @default.
• W2007509924 hasConceptScore W2007509924C146357865 @default.
• W2007509924 hasConceptScore W2007509924C151730666 @default.
• W2007509924 hasConceptScore W2007509924C2776256026 @default.
• W2007509924 hasConceptScore W2007509924C2776694085 @default.
• W2007509924 hasConceptScore W2007509924C2777910003 @default.
• W2007509924 hasConceptScore W2007509924C2778239845 @default.
• W2007509924 hasConceptScore W2007509924C2778822529 @default.
• W2007509924 hasConceptScore W2007509924C31760486 @default.
• W2007509924 hasConceptScore W2007509924C509974204 @default.
• W2007509924 hasConceptScore W2007509924C71924100 @default.
• W2007509924 hasConceptScore W2007509924C86803240 @default.
• W2007509924 hasIssue "1" @default.
• W2007509924 hasLocation W20075099241 @default.
• W2007509924 hasLocation W20075099242 @default.
• W2007509924 hasOpenAccess W2007509924 @default.
• W2007509924 hasPrimaryLocation W20075099241 @default.
• W2007509924 hasRelatedWork W2100029565 @default.
• W2007509924 hasRelatedWork W2277416945 @default.
• W2007509924 hasRelatedWork W2366392510 @default.
• W2007509924 hasRelatedWork W2376593068 @default.

• next